LENSAR, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LENSAR, Inc. (Nasdaq: LNSR) on May 12, 2023. The filing discloses the entry into a material definitive agreement for a private placement of equity securities. The Company is a Delaware corporation headquartered in Orlando, Florida, focused on ophthalmic laser systems.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: $20.0 million.
- Net Proceeds: Approximately $19.1 million after transaction expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Securities Issued:
- 20,000 shares of Series A Convertible Preferred Stock (stated value $1,000 per share).
- Warrants to purchase 4,367,246 shares of Common Stock.
- Conversion Terms: Preferred Shares are initially convertible into 7,940,446 shares of Common Stock at an initial conversion price of $2.51875 per share.
- Warrant Terms:
- 2,183,623 Class A Warrants with an exercise price of $2.45 per share.
- 2,183,623 Class B Warrants with an exercise price of $3.0625 per share.
- Warrants are exercisable for five years.
- Total Potential Dilution: Up to 12,307,693 shares of Common Stock upon conversion and exercise.
The filing does not provide current revenue, profit, cash flow, or debt figures; these are not applicable to this specific transaction report.
Material Changes and Governance
The transaction introduces significant changes to the Company's capital structure and governance:
- Ownership Blocker: Conversion of Preferred Shares is limited to prevent the Buyer (NR-GRI Partners, LP) from beneficially owning more than 19.99% of Common Stock. A special stockholder meeting must be held within 90 days to approve the removal of this blocker.
- Board Expansion: The Board of Directors will increase from seven to nine members effective after the May 25, 2023, Annual Meeting.
- New Directors: Thomas B. Ellis and Todd B. Hammer have been appointed as Board Designees by the Buyer.
- Restrictive Covenants: While the Buyer owns at least 20% of the underlying shares, the Company is restricted from incurring debt over $1.0 million, completing acquisitions over $1.0 million, or issuing significant equity without Buyer consent.
Outlook, Risks, and Contingencies
Management anticipates the transaction will close on or about May 18, 2023. The filing includes standard forward-looking statements regarding the ability to generate revenue, market acceptance of LENSAR Laser and ALLY Systems, and the impact of the COVID-19 pandemic. Specific risks highlighted include:
- History of operating losses and the need for additional capital.
- Regulatory approvals for the ALLY System.
- Competition from established market players.
- Supply chain disruptions.
The securities are being sold to accredited investors under Section 4(a)(2) and Regulation D exemptions and are not registered under the Securities Act of 1933 as of the closing date.
Investor Verification Checklist
- Verify the closing date of the Offering (anticipated May 18, 2023) and confirmation of net proceeds.
- Monitor the scheduling and outcome of the special stockholder meeting required to remove the 19.99% Ownership Blocker.
- Review the Company's most recent Form 10-Q for historical financial performance, as this 8-K does not contain operational metrics.
- Assess the impact of the new Board Designees and the expanded Board size on corporate strategy.
- Confirm the effectiveness of the resale registration statement for the Conversion Shares and Warrant Shares, which must be filed within 45 days of closing.